ALXO
ALX Oncology Holdings Inc.NASDAQHealthcare$1.97-0.51%ClosedMarket Cap: $106.8M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
4.10
P/S
0.00
EV/EBITDA
-0.95
DCF Value
$0.13
FCF Yield
-79.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-182.0%
ROA
-172.2%
ROIC
-262.0%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | NaN% | $-23.0M | $-22.8M | $-0.42 | — |
| FY 2025 | $0.00 | NaN% | $-100.8M | $-101.7M | $-1.90 | — |
| Q3 2025 | $0.00 | NaN% | $-22.5M | $-22.1M | $-0.41 | — |
| Q2 2025 | $0.00 | NaN% | $-26.6M | $-25.9M | $-0.49 | — |
| Q1 2025 | $0.00 | NaN% | $-31.8M | $-30.8M | $-0.58 | — |
| Q4 2024 | $0.00 | NaN% | $-30.6M | $-29.2M | $-0.55 | — |
| FY 2024 | $0.00 | NaN% | $-142.5M | $-134.8M | $-2.58 | — |
| Q3 2024 | $0.00 | NaN% | $-32.6M | $-30.7M | $-0.58 | — |
| Q2 2024 | $0.00 | -Infinity% | $-41.5M | $-39.4M | $-0.76 | — |
| Q1 2024 | $0.00 | -Infinity% | $-37.8M | $-35.6M | $-0.71 | — |
| Q4 2023 | $0.00 | NaN% | $-48.0M | $-45.5M | $-0.93 | — |
| FY 2023 | $0.00 | NaN% | $-170.3M | $-160.8M | $-3.74 | — |